Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935830 | 0.86 | GABRP (0.39) | HTR3AHTR2AHTR2C | |
| Bromide SCHEMBL11270772 | 0.83 | KDM1A (0.39) | KDM1AHTR2AHTR2C | |
| SCHEMBL6120653 | 0.82 | CYP2D6 (0.38) | HTR3APDE4BKDM1AHTR2AHTR2C | |
| SCHEMBL27752202 | 0.82 | KDM1A (0.44) | HTR3AKDM1AHTR2C | |
| SCHEMBL5807021 | 0.79 | — | — | |
| SCHEMBL1650443 | 0.76 | HRH4 (0.37) | HTR3AHTR2C | |
| SCHEMBL8368356 | 0.75 | — | — | |
| SCHEMBL1234810 | 0.73 | MAPT (0.42) | KDM1A | |
| SCHEMBL7144001 | 0.72 | MAPT (0.41) | KDM1A | |
| SCHEMBL1053967 | 0.72 | MAPT (0.41) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105516-B2 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2004026237-A2 | COMPOUNDS FOR THE TREATMENT OF PREMATURE EJACULATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | HTR5A, SLC18A2, CYP17A1 | HTR3A 60/4885PDE4B 207/4885KDM1A 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.